X. L. Wang
Impact in
-
- Protease and Inhibitor Mechanisms
- Pharmacology top 10%
- Drug-Induced Hepatotoxicity and Protection
Papers in
-
- Phenothiazines and Benzothiazines Synthesis and Activities 2
- Natural product bioactivities and synthesis 2
-
- Viral Infections and Outbreaks Research 2
- Viral Infections and Vectors 2
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Raouf A. Khalil (1 shared paper)Bernard Le Foll (1 shared paper)Yanli Liu (1 shared paper)Yu Liu (1 shared paper)Lin Lü (1 shared paper)Andrew Wolfe (1 shared paper)Chawnshang Chang (1 shared paper)Sally Radovick (1 shared paper)
- Journals
- Scientific Reports (3 papers)PLoS ONE (2 papers)Academic Radiology (1 paper)Ecological Indicators (1 paper)Chronic Respiratory Disease (1 paper)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
X. L. Wang
41 papers receiving 944 citations
X. L. Wang's Hit Papers
Peers
Comparison fields: 5 of 119
- Cancer Research 137
- Pharmacology 45
- Immunology 101
- Hepatology 32
- Virology 19
Countries citing papers authored by X. L. Wang
This map shows the geographic impact of X. L. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by X. L. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites X. L. Wang more than expected).
Fields of papers citing papers by X. L. Wang
This network shows the impact of papers produced by X. L. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by X. L. Wang. The network helps show where X. L. Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside X. L. Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease Hit paper breakdown → | 2017 | 541 |
| 2 | 2013 | 60 | |
| 3 | 2008 | 46 | |
| 4 | 2008 | 42 | |
| 5 | 2014 | 27 | |
| 6 | A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection. | 2011 | 25 |
| 7 | 2018 | 24 | |
| 8 | 2010 | 20 | |
| 9 | 2011 | 17 | |
| 10 | 2010 | 15 | |
| 11 | 2024 | 12 | |
| 12 | 2021 | 11 | |
| 13 | 2022 | 10 | |
| 14 | 2024 | 9 | |
| 15 | 2020 | 9 | |
| 16 | 2019 | 8 | |
| 17 | 2017 | 8 | |
| 18 | 2024 | 8 | |
| 19 | 2024 | 6 | |
| 20 | 2024 | 6 |
About X. L. Wang
X. L. Wang is a scholar working on Molecular Biology, Infectious Diseases, Pulmonary and Respiratory Medicine, Genetics and Surgery, having authored 48 papers that have together received 959 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Phenothiazines and Benzothiazines Synthesis and Activities (2 papers), Viral Infections and Outbreaks Research (2 papers), Venomous Animal Envenomation and Studies (2 papers), Malaria Research and Control (2 papers), Viral Infections and Vectors (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Natural product bioactivities and synthesis (2 papers). The work is most often cited by research in Cancer Research (137 citations), Pharmacology (45 citations), Immunology (101 citations), Hepatology (32 citations) and Virology (19 citations). X. L. Wang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Raouf A. Khalil, Bernard Le Foll, Yanli Liu, Yu Liu, Lin Lü, Andrew Wolfe, Chawnshang Chang, Sally Radovick, Ming Chen and Shuyuan Yeh. Their work appears in journals such as Scientific Reports, PLoS ONE, Academic Radiology, Ecological Indicators and Chronic Respiratory Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.